IBL Data Sheet

Code No. 10027

Anti-Human
Amyloid β (11-28) (12B2) Mouse IgG MoAb

Volume : 50 μg

Lot No : 9L-908

Introduction : Alzheimer's disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. The major protein component of these plaques is beta amyloid peptide(Aβ), a 40 to 43 amino acid peptide cleaved from amyloid precursor protein by beta-secretase and a putative γ secretase. Increased release of the 'longer forms' of Aβ peptide, Aβ42 or Aβ43, which have a greater tendency to aggregate than Aβ40, occurs in individuals expressing certain genetic mutations, expressing certain ApoE alles, or may involve other, still undiscovered, factors, Many researchers theorize that it is this increased release of Aβ42/Abeta 43 which leads to the abnormal deposition of Aβ and the associated neurotoxicity in the brains of affected individuals.

Antigen : Synthetic peptide for Human Amyloid [11-28]

Source : Mouse-Mouse hybridoma

Clone : 12B2

Subclass : IgG_1

Purification : Affinity Purified with antigen peptide

Form : Lyophilized product from 1% BSA in PBS containing 0.05%NaN_3

How to use : 0.5 ml distilled water will be added to the product

Dilution : PBS (pH7.4) containing 1% BSA

Stability : Lyophilized product, 5 years at 2 – 8 ℃
: Solution, 2 years at –20 ℃

Application : This antibody can be stained in formalin fixed paraffin embedded tissues after formic acid treatment*[1] by several Immunohistochemical techniques such as Avidin Bition Complex (ABC) Method. The optimal dilution is 0.25～1μg/ml, however, the dilution rate should be optimized by each laboratories.
*1 rinsing by running water after formic acid treatment for 5 minutes following de-paraffin.
: This antibody can be used for dot blotting in concentration of 2~5μg /ml.
: This antibody can be used for Immunoprecipitation.

Specificity : React with Human Amyloid β [1-40], [1-42] and [1-43]

Reference : Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, Yamaguchi H, Maeda M, Kinoshita N, Matsuoka Y. Development of Aβ terminal end-specific antibodies and sensitive ELISA for Aβ variant. Biochem Biophys Res Commun. 319(3):733-7, 2004.

IBL Co., LTD. 5-1 Aramachi, Takasaki-Shi, Gunma, 370-0831, JAPAN
TEL: +81 (0)27-310-8040 FAX: +81 (0)27-310-8045 URL: http://www.ibl-japan.co.jp E-Mail: do-ibl@ibl-japan.co.jp